Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma

Authors: Tran, Son ¹, Sipila, Patrick ¹, Frigault, Melanie M. ², Stelte-Ludwig, Beatrix ³, Johnson, Amy J. ², Birkett, Joseph ³, Izumi, Raquel ², Hamdy, Ahmed ², Maity, Ranjan ⁴, Bahlis, Nizar J. ⁴, Neri, Paola ⁴, Narendran, Aru ^{1, ∗}

Source: In Blood Neoplasia February 2025 2(1)

Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance

Authors: Lee, Holly, Neri, Paola, Bahlis, Nizar J.

Source: In Hematology/Oncology Clinics of North America April 2024 38(2):305-319

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms

Authors: Lee, Holly, Neri, Paola, Bahlis, Nizar J.

Source: In Blood 28 March 2024 143(13):1211-1217

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Authors: Leblay, Noémie, Ahn, Sungwoo, Tilmont, Rémi, Poorebrahim, Mansour, Maity, Ranjan, Lee, Holly, Barakat, Elie, Alberge, Jean-Baptiste, Sinha, Sarthak, Jaffer, Arzina, Barwick, Benjamin G., Boise, Lawrence H., Bahlis, Nizar, Neri, Paola

Source: In Blood 4 January 2024 143(1):42-56

Impact of soluble BCMA and non–T-cell factors on refractoriness to BCMA targeting T-cell engagers in multiple myeloma

Authors: Lee, Holly, Durante, Michael, Skerget, Sheri, Vishwamitra, Deeksha, Benaoudia, Sacha, Ahn, Sungwoo, Poorebrahim, Mansour, Barakat, Elie, Jung, David, Leblay, Noémie, Ziccheddu, Bachisio, Diamond, Benjamin, Papadimitriou, Marios, Cohen, Adam D., Landgren, Ola, Neri, Paola, Maura, Francesco, Bahlis, Nizar J.

Source: In Blood September 2024

Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma

Authors: Neri, Paola, Nijhof, Inger

Source: In Critical Reviews in Oncology / Hematology August 2023 188

Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop

Authors: Terpos, Evangelos, Neri, Paola, van de Donk, Niels W.C.J., D'Agostino, Mattia, Parekh, Samir, Jagannath, Sundar, Ludwig, Heinz, Avigan, David E., Dhodapkar, Madhav V., Raje, Noopur S.

Source: In Clinical Lymphoma, Myeloma and Leukemia June 2023 23(6):413-419

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Authors: Friedrich, Mirco J., Neri, Paola, Kehl, Niklas, Michel, Julius, Steiger, Simon, Kilian, Michael, Leblay, Noémie, Maity, Ranjan, Sankowski, Roman, Lee, Holly, Barakat, Elie, Ahn, Sungwoo, Weinhold, Niels, Rippe, Karsten, Bunse, Lukas, Platten, Michael, Goldschmidt, Hartmut, Müller-Tidow, Carsten, Raab, Marc-Steffen, Bahlis, Nizar J.

Source: In Cancer Cell 10 April 2023 41(4):711-725

Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone

Authors: Nie, Chunpeng, Lee, Holly, Tay, Jason, Duggan, Peter, McCulloch, Sylvia, Neri, Paola, Bahlis, Nizar J, Jimenez-Zepeda, Victor H

Source: In Clinical Lymphoma, Myeloma and Leukemia February 2023 23(2):104-111

Clinical and Pathological Characteristics of Non-AL Amyloidosis MGRS: A Single-Center Experience Over 10 Years.

Authors: Nie, Chunpeng, Lee, Holly, Cheema, Kim, Duggan, Peter, McCulloch, Sylvia, Tay, Jason, Neri, Paola, Bahlis, Nizar J., Jimenez-Zepeda, Victor H.

Source: Canadian Journal of Kidney Health & Disease; 2/21/2025, p1-8, 8p

Prevalence and Significance of Incidental PET/CT Findings of Cancer Detected in Patients Evaluated for Their Primary Hematologic Malignancy: A Systematic Review.

Authors: Luo, Jessie, Bahlis, Nizar J., Chan, Denise, Duggan, Peter, Jimenez-Zepeda, Victor H., Lee, Holly, McCulloch, Sylvia, Neri, Paola, Tay, Jason

Source: Current Oncology; Dec2024, Vol. 31 Issue 12, p7445-7458, 14p

Subject Terms: PLASMA cell diseases, POSITRON emission tomography, SECONDARY primary cancer, COMPUTED tomography, HEMATOLOGIC malignancies

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Authors: Munshi, Nikhil C., Avet-Loiseau, Herve, Anderson, Kenneth C., Neri, Paola, Paiva, Bruno, Samur, Mehmet, Dimopoulos, Meletios, Kulakova, Margarita, Lam, Annette, Hashim, Mahmoud, He, Jianming, Heeg, Bart, Ukropec, Jon, Vermeulen, Jessica, Cote, Sarah, Bahlis, Nizar

Source: In Blood Advances 8 December 2020 4(23):5988-5999

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Authors: Holstein, Sarah A., Howard, Alan, Avigan, David, Bhutani, Manisha, Cohen, Adam D., Costa, Luciano J., Dhodapkar, Madhav V., Gay, Francesca, Gormley, Nicole, Green, Damian J., Hillengass, Jens, Korde, Neha, Li, Zihai, Mailankody, Sham, Neri, Paola, Parekh, Samir, Pasquini, Marcelo C., Puig, Noemi, Roodman, G. David, Samur, Mehmet Kemal, Shah, Nina, Shah, Urvi A., Shi, Qian, Spencer, Andrew, Suman, Vera J., Usmani, Saad Z., McCarthy, Philip L.

Source: In Biology of Blood and Marrow Transplantation October 2020 26(10):e247-e255

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes

Authors: Diaz-Pallares, Carolina, Lee, Holly, Luider, Joanne, Duggan, Peter, Neri, Paola, Tay, Jason, MacCulloch, Sylvia, Bahlis, Nizar J., Jimenez-Zepeda, Victor H.

Source: In Clinical Lymphoma, Myeloma and Leukemia June 2020 20(6):394-399

Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary.

Authors: Lewis, Ellen, Fine, Nowell, McCulloch, Sylvia, Tay, Jason, Duggan, Peter, Neri, Paola, Bahlis, Nizar, Jimenez-Zepeda, Victor H.

Source: Current Oncology; Sep2024, Vol. 31 Issue 9, p5608-5616, 9p

Subject Terms: PROGRESSION-free survival, AMYLOIDOSIS, CARDIAC patients, DOXYCYCLINE, CARDIAC amyloidosis, BORTEZOMIB

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

Authors: Bahlis, Nizar J. ^*, Sutherland, Heather, White, Darrell, Sebag, Michael, Lentzsch, Suzanne, Kotb, Rami, Venner, Christopher P., Gasparetto, Cristina, Del Col, Aldo, Neri, Paola, Reece, Donna, Kauffman, Michael, Shacham, Sharon, Unger, T.J., Jeha, Jacqueline, Saint-Martin, Jean-Richard, Shah, Jatin, Chen, Christine

Source: In Blood 13 December 2018 132(24):2546-2554

Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience

Authors: Lee, Holly, Duggan, Peter, Chaudhry, Ahsan, Neri, Paola, Tay, Jason, Rashid-Kolvear, Fariborz, Bahlis, Nizar J., Jimenez-Zepeda, Victor H.

Source: In Clinical Lymphoma Myeloma and Leukemia January 2018 18(1):e69-e75

CD86 regulates myeloma cell survival

Authors: Gavile, Catherine M., Barwick, Benjamin G., Newman, Scott, Neri, Paola, Nooka, Ajay K., Lonial, Sagar, Lee, Kelvin P., Boise, Lawrence H. ^*

Source: In Blood Advances 28 November 2017 1(25):2307-2319

Representation of Actions in Rats: The Role of Cerebellum in Learning Spatial Performances by Observation

Authors: Leggio, Maria G., Molinari, Marco, Neri, Paola, Graziano, Alessandro, Mandolesi, Laura, Petrosini, Laura

Source: Proceedings of the National Academy of Sciences of the United States of America, 2000 Feb . 97(5), 2320-2325.

Access URL: https://www.jstor.org/stable/122041

Doubling down on GPRC5D in multiple myeloma

Authors: Neri, Paola

Source: Blood; January 2025, Vol. 145 Issue: 2 p146-148, 3p